TAAR1 agonists improve glycemic control, reduce body weight and modulate neurocircuits governing energy balance and feeding.
Journal Information
Full Title: Mol Metab
Abbreviation: Mol Metab
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:
"Declaration of competing interest ND, LW, PGJ, CS, SM, SCH, LJB and KSK are employees of Sumitomo Pharma America, Inc (formerly Sunovion Pharmaceuticals). EHK was an employee of Sunovion Pharmaceuticals at the time the studies were conducted. JHS and UR are employees of Gubra ApS. SPV is an employee of Sygnature Discovery. CA has received investigator-initiated research funding from Sumitomo Pharma America, Inc."
Funding Disclosure
Evidence found in paper:
"Funding This work was supported by funding from Sumitomo Pharma America Inc. and Otsuka Pharmaceuticals Development & Commercialization, Inc."
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025